يعرض 1 - 20 نتائج من 20 نتيجة بحث عن '"Govaerts A-S"', وقت الاستعلام: 0.46s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
  3. 3
  4. 4
    Academic Journal

    المساهمون: Van Akkooi, A. C. J., Hauschild, A., Long, G. V., Mandala', M., Kicinski, M., Govaerts, A. -S., Klauck, I., Ouali, M., Lorigan, P. C., Eggermont, A. M. M.

    Relation: info:eu-repo/semantics/altIdentifier/pmid/37665297; info:eu-repo/semantics/altIdentifier/wos/WOS:001057984800001; volume:19; issue:30; firstpage:2017; lastpage:2027; numberofpages:11; journal:FUTURE ONCOLOGY; https://hdl.handle.net/11391/1566836; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85174752310

  5. 5
    Conference

    المساهمون: Melanoma Institute Australia, Wollstonecraft, Australia

    Relation: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS9601; Van Akkooi ACJ, Hauschild A, Long GV, Mandalà M, Kicinski M, Govaerts AS, et al. Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005520.; http://hdl.handle.net/10541/626667; Journal of Clinical Oncology

  6. 6
  7. 7
    Conference

    المساهمون: University of Queensland, Princess Alexandra & Greenslopes PrivateHospital,Brisbane,QLD,Australia

    Relation: Atkinson VG, Hauschild A, Long GV, Mandala M, Kicinski M, Govaerts AS, et al. Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Asia-Pacific Journal of Clinical Oncology. 2022 Nov;18:115-. PubMed PMID: WOS:000871956500012.; http://hdl.handle.net/10541/625846; Asia-Pacific Journal of Clinical Oncology

  8. 8
    Conference

    المساهمون: Klinik für Dermatologie, Venerologie und Allergologie, Universitäts-klinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland

    Relation: Hauschild A, Van Akkooi ACJ, Long GV, Mandala M, Kicinski M, Govaerts AS, et al. Phase III study of adjuvant therapy with encorafenib plus binimetinib compared to placebo in completely resected BRAFV600-mutant stage IIB/C melanoma: study design of the COLUMBUS-AD. Journal Der Deutschen Dermatologischen Gesellschaft. 2022 Sep;20:96-. PubMed PMID: WOS:000851869200160.; http://hdl.handle.net/10541/625674; Journal Der Deutschen Dermatologischen Gesellschaft

  9. 9
    Academic Journal

    المساهمون: R. Galot, C. Le Tourneau, J. Guigay, L. Licitra, I. Tinhofer, A. Kong, C. Caballero, C. Fortpied, J. Bogaert, A. Govaert, D. Staelen, T. Raveloarivahy, L. Rodegher, J. Lae, E. Saada-Bouzid, J. Machiels

    مصطلحات موضوعية: Settore MED/06 - Oncologia Medica

    Relation: info:eu-repo/semantics/altIdentifier/pmid/30307465; info:eu-repo/semantics/altIdentifier/wos/WOS:000456859200011; volume:29; issue:12; firstpage:2313; lastpage:2327; numberofpages:15; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/2434/603472; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85059280488

  10. 10
    Academic Journal
  11. 11
    Academic Journal

    مصطلحات موضوعية: ddc:no

    Relation: Simon, C., Lefevre, C. Fortpied, Govaerts, A-S., Raveloarivahy, T., Bourhis, J., Evans, M., Klussmann, J. P., Leemans, C. R., Hunter, K. D., Singer, S., Nuyts, S., Willemse, E., Ansarin, M., Spriano, G., Golusinski, W., Giger, R., Boehm, A., Lopez, F. and Gregoire, V. (2022). Phase III study assessing the best of radiotherapy compared to the best of surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma. Ann. Oncol., 33 (7). S. S865 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

  12. 12
    Academic Journal

    المساهمون: R. Galot, C. Le Tourneau, E. Saada-Bouzid, A. Daste, C. Even, P. Debruyne, S. Henry, S. Zanetta, A. Rutten, L. Licitra, J.-. Canon, M.-. Kaminsky, P. Specenier, S. Rottey, J. Guigay, A. Kong, I. Tinhofer, E. Borcoman, L. Dirix, T. Raveloarivahy, C. Fortpied, M. Vanlancker, M. Morfouace, A.-. Govaert, J.-. Machiels

    Relation: info:eu-repo/semantics/altIdentifier/pmid/34638090; volume:158; firstpage:17; lastpage:26; numberofpages:10; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/2434/877230; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85116942347

  13. 13
    Academic Journal
  14. 14
    Academic Journal

    المساهمون: Van Laarhoven, H. W. M., Fiedler, W., Desar, I. M. E., van Asten, J. J. A., Marréaud, S., Lacombe, D., Govaerts, A. S., Bogaerts, J., Lasch, P., Timmer Bonte, J. N. H., Lambiase, A., Bordignon, Claudio, Punt, C. J. A., Heerschap, A., C. M. L., van Herpen

    Relation: volume:16; firstpage:1315; lastpage:1323; numberofpages:9; journal:CLINICAL CANCER RESEARCH; http://hdl.handle.net/20.500.11768/11724

  15. 15
    Academic Journal
  16. 16
    Academic Journal

    المصدر: Clamp , A R , Schöffski , P , Valle , J W , Wilson , R H , Marreaud , S , Govaerts , A S , Debois , M , Lacombe , D , Twelves , C , Chick , J & Jayson , G C 2008 , ' A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer ' , Cancer Chemotherapy and Pharmacology , vol. 61 , no. 4 , pp. 579-585 . https://doi.org/10.1007/s00280-007-0509-5

  17. 17
    Academic Journal
  18. 18
    Electronic Resource
  19. 19
    Academic Journal
  20. 20
    Academic Journal

    المؤلفون: Licitra, L.F.L.1 (AUTHOR), Locati, L.D.2 (AUTHOR), Digue, L.3 (AUTHOR), Even, C.4 (AUTHOR), Psyrri, A.5 (AUTHOR), Clement, P.M.6 (AUTHOR), Ochsenreither, S.7 (AUTHOR), Delord, J-P.8 (AUTHOR), Moro, C.9 (AUTHOR), Machiels, J-P.10 (AUTHOR), Fuereder, T.11 (AUTHOR), Govaerts, A-S.12 (AUTHOR), Quattrone, P.13 (AUTHOR), De Cecco, L.14 (AUTHOR), Perrone, F.15 (AUTHOR), Rasschaert, M.16 (AUTHOR), Nzokirantevye, A.17 (AUTHOR), Joaquim, A.17 (AUTHOR), Venslovaite, E.18 (AUTHOR), Fortpied Lefevre, C.19 (AUTHOR)

    المصدر: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1227-S1228. 2p.